Capricor Therapeutics Bolsa (NASDAQ: CAPR)

Últimas noticias sobre Capricor Therapeutics (NASDAQ:CAPR) Bolsa

Capricor Therapeutics

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

CAPRAL LTD by Capral Ltd.

CAPRI HOLDINGS ORD

Capri Holdings Ltd

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $77 price target.

News

Price Target

Reiteration

Analyst Ratings

CAPR

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target

WIIM

Capricor Therapeutics shares are trading higher after Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $25 to $30.

Analysts' ratings for Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Capricor Therapeutics, revealing an average target of $31.67, a high estimate of $77.00, and a low estimate of $8.00. Observing a 33.46% increase, the current average has risen from the previous average price target of $23.73. 
<img src="https://www.benzinga.com/files/images/story/2024/1731592835_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Capricor Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Capricor Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Capricor Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Capricor Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Capricor Therapeutics Better</h2>
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
<h3>Financial Milestones: Capricor Therapeutics's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Capricor Therapeutics showcased positive performance, achieving a revenue growth rate of 1.38% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Capricor Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -276.97%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Capricor Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -73.49%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Capricor Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -25.08%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.16, Capricor Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 12 Analyst Evaluations For Capricor Therapeutics

Cantor Fitzgerald analyst Kristen Kluska maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight and raises the price target from $25 to $30.

Cantor Fitzgerald Maintains Overweight on Capricor Therapeutics, Raises Price Target to $30

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. The company reported quarterly sales of $2.30 million which missed the analyst consensus estimate of $3.57 million by 35.54 percent. This is a 62.81 percent decrease over sales of $6.18 million the same period last year.

Earnings

Earnings Misses

Capricor Therapeutics Q3 2024 GAAP EPS $(0.38) Misses $(0.36) Estimate, Sales $2.30M Miss $3.57M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Capricor Therapeutics will report an earnings per share (EPS) of $-0.36.
Investors in Capricor Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 8.99% increase in the share price on the subsequent day.
Here's a look at Capricor Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.29</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.35</td>
<td>-0.31</td>
<td>-0.02</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-4.0%</td>
<td>9.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731420166_0.png" alt="eps graph" />
<h3>Performance of Capricor Therapeutics Shares</h3>
Shares of Capricor Therapeutics were trading at $19.54 as of November 11. Over the last 52-week period, shares are up 508.72%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CAPR/earnings">To track all earnings releases for Capricor Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Capricor Therapeutics

Deep-pocketed investors have adopted a bearish approach towards Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAPR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Capricor Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 27% leaning bullish and 54% bearish. Among these notable options, 3 are puts, totaling $146,410, and 8 are calls, amounting to $463,700.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $30.0 for Capricor Therapeutics over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Capricor Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Capricor Therapeutics's whale activity within a strike price range from $5.0 to $30.0 in the last 30 days. 
<h3>Capricor Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729714523_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.5</td>
<td>$15.7</td>
<td>$15.9</td>
<td>$5.00</td>
<td>$111.3K</td>
<td style="text-align: right;">803</td>
<td style="text-align: right;">70</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$16.6</td>
<td>$16.0</td>
<td>$16.3</td>
<td>$5.00</td>
<td>$81.5K</td>
<td style="text-align: right;">803</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$15.6</td>
<td>$14.2</td>
<td>$15.22</td>
<td>$30.00</td>
<td>$76.1K</td>
<td style="text-align: right;">58</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$25.00</td>
<td>$72.1K</td>
<td style="text-align: right;">216</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$25.00</td>
<td>$55.3K</td>
<td style="text-align: right;">216</td>
<td style="text-align: right;">158</td>
</tr>
</tbody>
</table>

<h3>About Capricor Therapeutics</h3>
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
After a thorough review of the options trading surrounding Capricor Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Capricor Therapeutics's Current Market Status</h3>
<ul>
<li>With a volume of 1,798,587, the price of CAPR is up 5.46% at $21.24. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 20 days.</li>
</ul>
<h3>Professional Analyst Ratings for Capricor Therapeutics</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $44.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $35. 
&#x2A; An analyst from HC Wainwright &amp; Co. has decided to maintain their Buy rating on Capricor Therapeutics, which currently sits at a price target of $77. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $40. 
&#x2A; An analyst from Maxim Group has decided to maintain their Buy rating on Capricor Therapeutics, which currently sits at a price target of $25. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Capricor Therapeutics, targeting a price of $43. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Capricor Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Capricor Therapeutics Options Trading: A Deep Dive into Market Sentiment

Capricor Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a price target of $35.

Piper Sandler analyst Edward Tenthoff initiates coverage on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight rating and announces Price Target of $35.

Initiation

Piper Sandler Initiates Coverage On Capricor Therapeutics with Overweight Rating, Announces Price Target of $35

Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares are trading lower by 6.05% to $19.27 during Thursday&#8217;s session. The company earlier commenced its <a href="https://www.benzinga.com/pressreleases/24/10/g41375519/capricor-therapeutics-announces-pricing-of-approximately-75-million-public-offering-of-common-stoc">public offering of common stock</a>.
What To Know: The company announced the pricing of its public offering of 4.41 million shares at $17.00 per share. The company granted underwriters a 30-day option to purchase an additional 661,800 shares. 
The offering, expected to close on October 18, will raise approximately $75 million before expenses and commissions. 
Piper Sandler &amp; Co. and Oppenheimer &amp; Co. Inc. are managing the offering. Capricor says the company plans to use the funds for product development, manufacturing, working capital, and general corporate purposes.
Stock Of The Day: <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41383732/stock-of-the-day-taiwan-semiconductor-breaks-out-as-buyers-push-prices-higher">Taiwan Semiconductor Breaks Out As Buyers Push Prices Higher</a>
<h2 class="wp-block-heading">Should I Sell My CAPR Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Capricor Therapeutics stock currently has an RSI of 61.26, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>

Why Capricor Therapeutics (CAPR) Shares Are Trading Lower

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.
Shares of CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41369567/csx-stock-falls-after-worse-than-expected-q3-results-details">third-quarter earnings below analyst estimates.</a>
CSX reported quarterly GAAP earnings of 46 cents per share, which missed the consensus estimate of 48 cents per share. Quarterly revenue came in at $3.62 billion, also missing the consensus estimate of $3.676 billion. The company said its total volume of 1.59 million units for the quarter was 3% higher as compared to the third quarter of 2023.
CSX shares dipped 5.4% to $33.55 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares dipped 16.2% to $3.37 in pre-market trading after surging 122% on Wednesday.</li>
<li>Lucid Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) declined 14.6% to $2.80 in pre-market trading after the company announced a public offering of common stock, along with a corresponding investment by an affiliate of the Public Investment Fund.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares fell 13.2% to $0.6350 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares fell 10.6% to $18.33 in pre-market trading. The company commenced its public offering of common stock.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares fell 8.8% to $1.64 in pre-market trading after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>KE Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NASDAQ">BEKE</a>) shares declined 7.7% to $20.23 in pre-market trading after gaining around 5% on Wednesday.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) shares fell 6.4% to $15.41 in pre-market trading.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) shares fell 5.4% to $4.22 in pre-market trading following downbeat third-quarter results. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

BEKE

CERS

LCID

LILM

MNSO

PRQR

CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Capricor Therapeutics shares are trading lower. The company commenced its public offering of common stock.

The gross proceeds from the offering are expected to be approximately&nbsp;$75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Capricor and assuming no exercise of the underwriters&#39; option.

Offerings

Capricor Therapeutics Prices Public Offering Of 4.412M Shares Of Common Stock At $17.00 Per Share

<h3>Gainers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock increased by 189.2% to $0.94 during Wednesday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 21.72% to $0.68. The company's market cap stands at $14.5 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 12.23% to $1.0. The market value of their outstanding shares is at $5.7 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares moved upwards by 5.9% to $6.99. The market value of their outstanding shares is at $130.3 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock rose 5.17% to $18.5. The company's market cap stands at $117.3 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) shares moved upwards by 5.08% to $1.24. The company's market cap stands at $88.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares fell 14.8% to $0.54 during Wednesday's after-market session. The company's market cap stands at $20.4 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 12.74% to $7.33. The market value of their outstanding shares is at $106.4 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock decreased by 11.07% to $18.24. The company's market cap stands at $644.5 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 10.98% to $5.76. The company's market cap stands at $5.9 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 10.4% to $0.56. The company's market cap stands at $11.7 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined by 9.45% to $1.63. The market value of their outstanding shares is at $302.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASMB

ATNF

BDRX

CHRO

CTCX

HCWB

KLTO

MTEM

NVCT

OVID

12 Health Care Stocks Moving In Wednesday's After-Market Session

Capricor Therapeutics Commences Public Offering Of Common Stock; Terms Not Disclosed

Capricor Therapeutics May Offer And Sell Up To $150M In Common Stock, Preferred Stock, Debt Securities, Warrants, And Units In One Or More Offerings

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$116.00</td>
<td>$116.9K</td>
<td>3.7K</td>
<td>3.7K</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$100.00</td>
<td>$66.3K</td>
<td>2.4K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MOH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$330.00</td>
<td>$156.4K</td>
<td>55</td>
<td>720</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.00</td>
<td>$77.0K</td>
<td>3</td>
<td>550</td>
</tr>
<tr>
<td>EWTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$35.00</td>
<td>$30.0K</td>
<td>16</td>
<td>300</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/25/24</td>
<td>$27.50</td>
<td>$29.0K</td>
<td>145</td>
<td>293</td>
</tr>
<tr>
<td>SMMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$20.00</td>
<td>$53.0K</td>
<td>293</td>
<td>246</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$60.00</td>
<td>$76.5K</td>
<td>1.1K</td>
<td>120</td>
</tr>
<tr>
<td>GPCR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$40.00</td>
<td>$121.0K</td>
<td>175</td>
<td>100</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$275.00</td>
<td>$31.5K</td>
<td>590</td>
<td>68</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a put option trade with neutral sentiment. It expires in 2 day(s) on October 18, 2024. Parties traded 2924 contract(s) at a $116.00 strike. The total cost received by the writing party (or parties) was $116.9K, with a price of $40.0 per contract. There were 3761 open contracts at this strike prior to today, and today 3738 contract(s) were bought and sold. 
• Regarding DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we observe a call option sweep with bearish sentiment. It expires in 93 day(s) on January 17, 2025. Parties traded 603 contract(s) at a $100.00 strike. This particular call needed to be split into 81 different trades to become filled. The total cost received by the writing party (or parties) was $66.3K, with a price of $110.0 per contract. There were 2415 open contracts at this strike prior to today, and today 1605 contract(s) were bought and sold. 
• Regarding MOH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), we observe a call option trade with bullish sentiment. It expires in 2 day(s) on October 18, 2024. Parties traded 549 contract(s) at a $330.00 strike. The total cost received by the writing party (or parties) was $156.4K, with a price of $285.0 per contract. There were 55 open contracts at this strike prior to today, and today 720 contract(s) were bought and sold. 
• Regarding CAPR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), we observe a call option trade with bearish sentiment. It expires in 247 day(s) on June 20, 2025. Parties traded 50 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $77.0K, with a price of $1540.0 per contract. There were 3 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a put option sweep with bearish sentiment. It expires in 2 day(s) on October 18, 2024. Parties traded 300 contract(s) at a $35.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $100.0 per contract. There were 16 open contracts at this strike prior to today, and today 300 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on October 25, 2024. Parties traded 100 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $290.0 per contract. There were 145 open contracts at this strike prior to today, and today 293 contract(s) were bought and sold. 
• Regarding SMMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), we observe a call option trade with neutral sentiment. It expires in 30 day(s) on November 15, 2024. Parties traded 100 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $53.0K, with a price of $530.0 per contract. There were 293 open contracts at this strike prior to today, and today 246 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 93 day(s) on January 17, 2025. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $76.5K, with a price of $1530.0 per contract. There were 1168 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold. 
• For GPCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>), we notice a call option trade that happens to be bullish, expiring in 429 day(s) on December 19, 2025. This event was a transfer of 100 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $121.0K, with a price of $1210.0 per contract. There were 175 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 16 day(s) on November 1, 2024. This event was a transfer of 60 contract(s) at a $275.00 strike. The total cost received by the writing party (or parties) was $31.5K, with a price of $526.0 per contract. There were 590 open contracts at this strike prior to today, and today 68 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXCM

EWTX

GPCR

SAVA

SMMT

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) has outperformed the market over the past 5 years by 32.37% on an annualized basis producing an average annual return of 46.55%. Currently, Capricor Therapeutics has a market capitalization of $616.28 million. 
Buying $1000 In CAPR: If an investor had bought $1000 of CAPR stock 5 years ago, it would be worth $6,785.99 today based on a price of $17.44 for CAPR at the time of writing.
<h3>Capricor Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728677024_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,800 Today

Piper Sandler initiated coverage of Capricor Therapeutics (CAPR) with an Overweight rating and $35 price target Capricor is developing deramiocel t...

Capricor Therapeutics initiated with an Overweight at Piper Sandler

17:13 EDT Capricor Therapeutics (CAPR) files to sell 2.8M shares of common stock for holders Published first on TheFly – the ultimate source for re...

Capricor Therapeutics files to sell 2.8M shares of common stock for holders

Here are the major earnings after the close today

Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with calls leading puts 3:1. Implied volatility suggests the market is antici...

Capricor Therapeutics options imply 8.1% move in share price post-earnings

Capricor Therapeutics GAAP EPS of -$0.38 misses by $0.02, revenue of $2.3M misses by $1.27M

Reports Q3 revenue $2.3M, consensus $3.57M. Cash, cash equivalents and marketable securities totaled approximately $85.0M as of September 30, 2024 ...

Capricor Therapeutics reports Q3 EPS (38c), consensus (36c)

Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript

Capricor Therapeutics, Inc. ( ($CAPR) ) has released its Q3 earnings. Here is a breakdown of the information Capricor Therapeutics, Inc. presented ...

Capricor Therapeutics Advances with Strategic Expansions

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The associated pric...

Capricor Therapeutics: Strategic Positioning and Financial Stability Drive Buy Rating

Today's macro environment reflects a strong risk-on sentiment, fueled by a notable rally in Bitcoin, which has surged past the $90,000 threshold.

Space, Biotech, And More: Today's Hottest Stocks To Watch

AOIFF

ASTS

BDORY

LUNR

NLCP

PVCT

SMSI

SONO

SPRU

TLPH

TTEK

VXRT

Press Releases

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Health Care

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Financing

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

Comments

Capricor Therapeutics

Noticias

Últimas noticias sobre Capricor Therapeutics (NASDAQ:CAPR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL